Per today's PR: "Innovation Pharmaceuticals est
Post# of 72439
"Innovation Pharmaceuticals established the subsidiary as part of its commitment to expand development its clinical pipeline—including Brilacidin, its Host Defense Protein-mimetic drug candidate with multiple therapeutic applications, and Kevetrin, its p53-modulating anti-cancer drug candidate—for the European marketplace"
Commitment to WHOM?
Kelt